Christopher James
Papers
2
Total Citations
109
H-Index
2
About
Christopher James has made significant contributions to bioanalytical chemistry, with a primary focus on the quantitation of anticancer therapeutics in biological matrices. His key research areas include the development and validation of liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods for pharmacokinetic studies, particularly for tyrosine kinase inhibitors and chemotherapeutic agents. James is best known for his pioneering work on SU11248 (sunitinib), an oral multi-target tyrosine kinase inhibitor, where he established a robust method for quantifying the drug and its active metabolite in monkey tissues using semi-automated liquid-liquid extraction coupled with LC-MS/MS—a technique that has garnered 60 citations and remains foundational in preclinical drug development. His equally impactful work on paclitaxel quantification in human plasma (49 citations) demonstrated his ability to translate complex analytical methods to clinical settings. These contributions have been instrumental in advancing the understanding of drug distribution and metabolism, directly supporting the development of targeted cancer therapies. James’s meticulous approach to bioanalytical method development has set standards for reproducibility and sensitivity, making him a respected figure in pharmaceutical analysis and a key enabler of translational oncology research.
Research Focus
Key Achievements
Top Papers
- 1
- 2